The prognostic value of mitotic rate in melanoma is increasingly recognized, particularly in thin melanoma in which the presence or absence of a single mitosis/mm 2 can change staging from T1a to T1b. Still, accurate mitotic rate calculation (mitoses/mm 2 ) on hematoxylin and eosin (H&E)-stained sections can be challenging. Antimonoclonal mitotic protein-2 (MPM-2) and antiphosphohistone-H3 (PHH3) are 2 antibodies reported to be more mitosis-specific than other markers of proliferation such as Ki-67. We used light microscopy and computer-assisted image analysis software to quantify MPM-2 and PHH3 staining in melanoma. We then compared mitotic rates by each method with conventional H&E-based mitotic rate for correlation with clinical outcomes. Our study included primary tissues from 190 nonconsecutive cutaneous melanoma patients who were prospectively enrolled at New York University Langone Medical Center with information on age, gender, and primary tumor characteristics. The mitotic rate was quantified manually by light microscopy of corresponding H&E-stained, MPM-2-stained, and PHH3-stained sections. Computer-assisted image analysis was then used to quantify immunolabeled mitoses on the previously examined PHH3 and MPM-2 slides. We then analyzed the association between mitotic rate and both progression-free and melanoma-specific survival. Univariate analysis of PHH3 found significant correlation between increased PHH3 mitotic rate and decreased progression-free survival (P = 0.04). Computer-assisted image analysis enhanced the correlation of PHH3 mitotic rate with progression-free survival (P = 0.02). Regardless of the detection method, neither MPM-2 nor PHH3 offered significant advantage over conventional H&E determination of mitotic rate.
M itotic rate is traditionally evaluated by counting mitotic figures on hematoxylin and eosin (H&E)stained tissue sections. This count has been used to predict aggressive behavior in several neoplasms. [1] [2] [3] In melanoma, mitotic rate has been found to have an independent prognostic value in primary melanomas of all thicknesses. [4] [5] [6] [7] [8] [9] This finding has led the American Joint Committee on Cancer (AJCC) to adopt mitotic rate in the current staging system for thin (r1 mm) nonulcerated melanomas. 5, 6 Staging systems for other neoplasms, such as for breast carcinoma, use mitotic rate for prognostic categories whose cutoffs may be separated by several mitoses seen across multiple high-power fields. 2, 10 In contrast, stage T1a melanoma may differ from T1b melanoma by the presence or absence of a single mitosis/mm 2 . 6 As important as accurate mitotic rate assessment is in melanoma, its calculation on routine histology can be challenging. 11, 12 Factors such as heavy pigmentation, high cellularity, pyknotic debris, and necrosis may obscure mitotic figures. Immunohistochemical markers have been investigated as surrogates for mitotic rate with conflicting results. One example is MIB-1, an antibody against the Ki-67 nuclear antigen. Ki-67 is a cell proliferation marker expressed during all phases of the cell cycle except G0 and early G1. Several studies report an association between increased Ki-67 staining and poor outcome in melanoma. 13, 14 Other studies argue that despite an association with poor outcome, Ki-67 is not an independent prognostic factor. 15 As Ki-67 lacks definitive independent prognostic significance, it has not been incorporated into the melanoma staging system. Antimitotic protein monoclonal-2 (MPM-2) and antiphosphohistone-H3 (PHH3) are 2 relatively new antibodies that differ from earlier surrogate markers of proliferation in that their respective epitopes are restricted to the M phase. Thus, they are potentially more specific and sensitive markers of mitosis. MPM-2 recognizes phosphoprotein epitopes on mitosis-specific molecules, including topoisomerase IIa, microtubule-associated proteins, and Cdc2-inhibitory kinases. [16] [17] [18] PHH3 binds more specifically to epitopes of histone H3 that are selectively phosphorylated during mitosis. 19 Recent data suggest that PHH3 immunostaining significantly increases interobserver agreement in mitotic rate calculation in thin melanomas. 20 The aim of the present study was to compare the prognostic value of traditional H&E-based mitotic rate with mitotic rate calculated using computer-assisted image analysis and mitosis-specific immunostaining.
MATERIALS AND METHODS

Sources of Tissue
The study cohort consisted of primary melanoma patients enrolled in the Interdisciplinary Melanoma Cooperative Group, a prospectively collected, clinicopathologic biospecimen database for melanoma at New York University Langone Medical Center. 21 Informed consent was obtained from all patients at the time of enrollment. Nonconsecutive patients were selected by first identifying those with available primary tissue for immunohistochemistry and a minimum follow-up of 2.5 years from the date of pathologic diagnosis. Primary melanoma patients meeting these 2 criteria were then divided into 2 groups: recurrent versus nonrecurrent, and matched for age at initial melanoma diagnosis, gender, primary tumor thickness (mm), ulceration, mitosis (absent vs. present), histotype, and anatomic site (Table 1) . A total of 190 patients were included in this study whose primary tumors ranged from 0.4 to 30 mm in thickness.
Immunohistochemistry
Immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded tissues using rabbit anti-human phosphorylated (serine 28) histone H3 (PHH3; Abcam, Cambridge, MA) and mouse anti-human mitotic protein monoclonal-2 (MPM-2; Millipore, Billerica, MA). Sections were deparaffinized in xylene (3 changes), rehydrated through graded alcohols (3 changes 100% ethanol, 3 changes 95% ethanol), and rinsed in distilled water. Heat-induced epitope retrieval was performed in 10 mM citrate buffer pH 6.0 for 20 minutes in a 1200 W microwave oven at 100% power. Sections were allowed to cool for 30 minutes and then rinsed in distilled water. Antibody incubations and detection were carried out at 371C on a NEXes instrument (Ventana Medical Systems, Tucson, AZ) using Ventana's reagent buffer and detection kits unless otherwise noted. PHH3 was diluted to 1:60 and MPM-2 to 1:600 in phosphate-buffered saline and allowed to incubate overnight at room temperature. Primary antibodies were detected with Ventana's biotinylated goat anti-mouse or goat anti-rabbit, followed by streptavidin-alkaline phosphatase conjugate. The complex was visualized with Naphthol-AS-MX phosphatase and Fast Red complex (Ventana Medical Systems). Slides were washed in distilled water, counterstained with hematoxylin, dehydrated, and mounted with permanent media. Appropriate positive and negative controls were included with the study sections.
Mitotic Rate Calculation
We compared the primary tumor mitotic rate calculation obtained by conventional light microscopic assessment with that by computer-assisted image analysis (Aperio, Vista, CA). Light microscopic assessment was performed on H&E-stained tissue sections and on corresponding sections stained with anti-MPM-2 and anti-PHH3 immunostains. Aperio detection algorithms are optimized for use with immunolabeled cells, therefore computer-assisted analysis of mitotic rate was performed on antibody-stained sections only.
Conventional mitotic rate was calculated simultaneously by 2 pathologists (F.D. and C.S.H.) with different levels of experience (7 y practicing and 4 y in-training, respectively). Tissue sections of 5 mm thickness were stained with H&E, anti-MPM-2, or anti-PHH3. In accordance with current AJCC recommendations, the area of tumor with greatest mitotic activity was identified (the "hotspot"). 6 After counting the number of mitotic figures in this field, the count was extended to adjacent fields until an area of 1 mm 2 was assessed. Each microscope used was calibrated to determine the number of Â 40 fields equivalent to 1.0 mm 2 .
Computer-assisted analysis was performed on immunohistochemically stained slides digitally scanned at Â 20 using a ScanScope digital pathology system (Aperio). The digital slides were visualized using the ImageScope viewer (Aperio). For each digital slide, the area of tumor with the greatest mitotic activity was manually identified. Using the cursor, a region of interest surrounding the hotspot was outlined, with exclusion of nontumoral areas. This region of interest was progressively enlarged until at least 1.0 mm 2 of tumor was outlined. On digital slides with <1.0 mm 2 of total tumor area, the entire area of the tumor was selected. The Aperio nuclear quantification algorithm was then executed to calculate the number of immunolabeled cells within the region of interest. Default settings for the nuclear analysis algorithm (Aperio "Nuclear v9") were used. Optical density settings for Fast Red chromogen were provided by the algorithm manufacturer. The algorithm reported positive cell counts, stratified by intensity of staining (weak, intermediate, strong). Strongly staining cells with appropriate morphology were considered positive ( Fig. 1 ). For sections containing <1.0 mm 2 of tumor, the computer-assisted mitotic rate was recorded as the absolute number of positive cells. For digital slides with tumor area exceeding 1.0 mm 2 , the mitotic rate was recorded as the number of positive cells/1.0 mm 2 .
Statistical Methods
Descriptive statistics were used to summarize patient characteristics. The association between conventional light microscopic evaluation and computer-assisted PHH-3 and MPM-2 analysis was measured using the Pearson correlation coefficient. The association between progression-free survival and mitotic rate (either visually assessed or computer generated) was evaluated using the Cox regression model. Kaplan-Meier curves and log rank tests were used to assess differential survival profiles of risk groups. Statistical significance of tests was claimed when P values were <0.05. Statistical analyses were conducted using SAS (version 9.2) and the statistical software R.
RESULTS
A total of 190 patients (72 female, 118 male) were included in the study ( Table 1 ). The cases were distributed across AJCC stages IA to IIC (IA: N = 12; IB: N = 72; IIA: N = 52; IIB: N = 28; and IIC: N = 26). The median progression-free survival was 40 months (3.3 y). Median follow-up was 56 months (4.7 y) for the whole cohort and 66.5 months (5.5 y) for survivors. The distribution of 2009 AJCC T stages was as follows: T1a 6% (12/190), T1b 5% (10/190), T2a 33% (62/190), T2b 12% (22/190), T3a 16% (30/190), T3b 11% (20/190), T4a 4% (8/190), and T4b 14% (26/190 ). Average Breslow thickness was 3.02 mm (range, 0.4 to 30 mm). Multiple primary lesions were present in 5% (10/190) of patients in the cohort. Of these, the thickest primary was selected as the index primary in 8/10 cases. The invasive primary lesion was selected as the index lesion for the remaining 2/10 patients, each of whom presented with a solitary invasive lesion and multiple lesions of melanoma in situ.
As patients were selected for recurrence, the majority of primary tumor cases selected (168/190; 88%) were >1 mm in thickness. Thin melanomas had a low rate of recurrence such that they only comprised a minority of the cases in this study (22/190; 12%) . Selection 14 12 was also reflected in the ratio of histologic subtypes: 113/ 190 (59%) were of the nodular melanoma subtype and 70/ 190 (37%) were of the superficial spreading melanoma subtype. Thicker melanomas had a higher rate of recurrence and were mostly of the nodular melanoma subtype, consistent with the aggressive biology of nodular melanoma. 22 Owing to selection of equal numbers of recurring and nonrecurring cases in each category, the clinicopathologic variables analyzed (age at initial melanoma diagnosis, gender, primary tumor thickness, ulceration, presence or absence of mitosis, histologic type, and site) were not significantly associated with recurrence on the Fisher exact test (Table 1) . A separate w 2 analysis, however, confirmed that the presence of either ulceration or thickness >4 mm showed the expected significant association with increased mitotic rate by conventional H&E, computer-assisted PHH3, and manual PHH3 methods ( Table 2) . Of the 380 immunohistochemically stained sections, 46/190 (24%) MPM-2 and 18/190 (9%) PHH3-stained sections exhibited less than optimal staining, as defined by the following criteria: (1) MPM-2 and/or PHH3 labeling in nonbasal keratinocytes; (2) sections with heavy background melanin pigment. These sections were excluded Am J Surg Pathol Volume 37, Number 6, June 2013 Mitotic Rate in Melanoma from statistical analysis. In 11/190 (6%) cases, residual tumor was absent from both of the deeper sections used for immunostaining. These cases were also excluded from statistical analysis. Compared with the corresponding H&E-stained sections, both antibodies led to higher manual mitotic counts by conventional light microscopy and computer-assisted analysis (Fig. 2) . Although absolute mitotic counts by computer-assisted analysis were higher, the mitotic rate by computer-assisted analysis of PHH3 and MPM-2 very significantly correlated with the manual mitotic rate by light microscopic evaluation of PHH3 and MPM-2 (+0.501 for MPM-2, P < 0.0001; +0.587 for PHH3, P < 0.0001). Both PHH3 and MPM-2 facilitated rapid localization of the mitotic "hotspot."
Mitotic Rate and Progression-free Survival
Univariate Cox analysis of all cases showed a significant correlation between progression-free survival and mitotic rate by traditional H&E, manual PHH3, and computer-assisted PHH3 methods (P = 0.004, 0.04 and 0.02, respectively). Separating the cohort into cases r1.0 mm thick and cases >1.0 mm thick found no significant correlation between mitotic rate and progressionfree survival in the thinner cases by univariate Cox analysis. In thicker melanomas (> 1.00 mm), univariate Cox analysis found significant correlation between increased mitotic rate and decreased progression-free survival by H&E and by computer-assisted PHH3 methods (P = 0.01 and 0.04, respectively). Relative to the subset of melanomas >1.0 mm, there was a trend toward better progression-free survival when melanomas of all thicknesses were considered together, both by univariate and multivariate analysis.
Multivariate Cox analysis of all cases (including age at initial melanoma diagnosis, primary tumor thickness, ulceration status, mitotic rate, anatomic site) found that only H&E mitotic rate was significant for progressionfree survival (P = 0.02). Multivariate Cox analysis of melanomas >1.00 mm found only the H&E mitotic rate to be significant (P = 0.035).
Kaplan-Meier analysis of manual mitotic rates showed that high mitotic rate, whether by H&E or by PHH3 ( Figs. 3, 4) , was significantly associated with decreased estimated 5-year progression-free survival in thicker melanomas (> 1.00 mm). As a group, those cases with manual H&E mitotic rates above the median (2 mitoses/mm 2 ) had significantly worse 5-year progressionfree survival compared with those with manual H&E mitotic rates below the median (P = 0.0002). Similarly, cases with manual PHH3 mitotic rates above the median (4 mitoses/mm 2 ) had significantly worse 5-year progression-free survival compared with those with manual PHH3 mitotic rates below the median (P = 0.020). No year recurrence in all melanomas. Group 1 includes those melanomas with mitotic rate less than the median value for H&E staining (2 mitoses/mm 2 ). Group 2 includes those melanomas with mitotic rate no less than the median value for H&E staining. A significant difference in the 5-year estimated progression-free survival function is seen between cases with lower and higher H&E mitotic rate (0.654 and 0.372, respectively; P = 0.00009). . Visually calculated PHH3 mitotic rate and progression-free survival. Kaplan-Meier curve and log rank test on recurrence in all melanomas. Group 1 includes those melanomas with mitotic rate less than the median value for PHH3 labeling (4 mitoses/mm 2 ). Group 2 includes those melanomas with mitotic rate no less than the median value for PHH3 labeling. A significant difference is seen in the 5-year estimated progression-free survival function seen between cases with lower and higher PHH3 labeling (0.608 and 0.464, respectively; P = 0.013).
significant correlation between progression-free survival and MPM-2 mitotic rate was seen by manual or computer-assisted methods.
Mitotic Rate and Melanoma-specific Survival
Univariate Cox analysis of all cases showed a significant correlation between melanoma-specific survival and mitotic rate by H&E only (P = 0.02). Multivariate Cox analysis found that none of the mitotic rate detection methods (manual or computer-assisted image analysis, H&E or immunostain) significantly correlated with melanoma-specific survival. Similar to progression-free survival, there was a trend toward better melanoma-specific survival relative to the subset of melanomas >1.0 mm when melanomas of all thicknesses were considered together, both by univariate and multivariate analysis.
DISCUSSION
Computer-assisted image analysis has existed in some form since as early as 1987, but software for analysis of histologic features has only recently become available. 23, 24 In this study, we tested whether the use of 2 mitosis-specific antibodies could "flag" mitotically active cells such that immunopositivity could be detected using commercially available computer image analysis software. In cutaneous melanoma, this is the first time conventional light microscopy has been compared with computer-assisted analysis for detection of immunolabeled mitoses. Data from the breast carcinoma literature suggest that both manual and computer-assisted quantification of H&E-immunostained and PHH3-immunostained mitoses correlate well, but comparable data for melanoma has not been published. 25, 26 The previous study of computer-assisted detection of PHH3-labeled mitoses in breast carcinoma relied on immunofluorescence and confocal microscopy. 25 We avoided these methods in favor of routine immunohistochemical stains, easily performed in most diagnostic laboratories. The use of immunohistochemistry instead of immunofluorescence also permitted evaluation of immunolabeled mitotic figures with consideration to the size and location of the targeted cells. Tumor areas were easily distinguishable by this method, allowing us to restrict computer-assisted and manual analysis of PHH3-stained mitotic cells to tumoral tissue.
The majority of the cases in the study (88%; 168/190) were intermediate or thick primaries. Surprisingly, 25% (49/190) of the cases had an H&E mitotic rate of <1/mm 2 . Although the number of cases with a mitotic rate <1/mm 2 is relatively high, we note that mitosis was scored as the mitotic rate per 10 high-power fields before the 2009 new staging system. In the process of rereviewing all of the cases in the cohort again to comply with the new staging definition (mitosis/mm 2 ), the mitotic rate reduced substantially. Although this might not fully explain the relative high frequency of low mitotic rate in our cohort in general, the second review of all the cases gives us confidence in the accuracy of the H&E mitotic rate counts.
Technical aspects of immunostaining are likely to limit the use of PHH3 and MPM-2 in routine practice. Despite optimization of our staining protocols in prestudy pilots, a percentage of cases continued to have unsatisfactory staining with both antibodies. Endogenous alkaline phosphatases are a known cause of unsatisfactory staining with the Fast Red chromogen; however, our commercial kit included levamisol as an inhibitor of endogenous alkaline phosphatase. We do not have data on time to formalin fixation for the tissues in our study and cannot exclude the effects of variable fixation on the performance of PHH3 and MPM-2 stains. It is also possible that some of the unsatisfactory staining we observed may be because of factors intrinsic to the specimens themselves. No observable correlation was seen between unsatisfactorily stained cases and particular staining runs or instruments.
The cost of performing the immunostains, in terms of time and money, is another limitation to clinical use of mitosis-specific antibodies. Although there was a subjective decrease in the time needed to calculate the mitotic rate from immunostained sections, this observation does not take into account that the pathologist, when assessing the H&E-stained slides for mitotic rate in routine practice, will have had to evaluate the H&E slide(s) in order to diagnose and report the melanoma. When the pathologists begins mitotic rate calculation, they are not beginning "from scratch" to determine the mitotic rate. This may lead to an overestimation of the time it takes to determine the mitotic rate on H&E slides. As an H&E-stained slide must be generated regardless of whether immunostaining is used, the benefit of immunostaining does not seem to justify the additional time, labor, and materials.
Univariate analysis of PHH3 found significant correlation between the increased PHH3 mitotic rate and decreased progression-free survival (P = 0.04). Computerassisted image analysis enhanced the correlation of the PHH3 mitotic rate with progression-free survival (P = 0.04 to 0.02). Regardless of the detection method, neither MPM-2 nor PHH3 offered significant advantage over conventional H&E determination of mitotic rate. Considered separately, however, we did find additional benefits to the use of PHH3 and computer-assisted image analysis.
In our opinion, PHH3 immunostaining also allows more objective determination of the mitotic count, as apoptotic cell debris is more easily distinguished from mitoses. This objectivity is reflected in the enhanced interobserver agreement that has been reported with PHH3 staining in thin cutaneous melanoma 20 and uveal melanoma. 27 Moreover, PHH3 staining permits recognition of mitotic cells that lack the easily recognizable morphology of metaphase or anaphase. Our data showed that, relative to H&E, manual quantification of PHH3 increased the average mitotic rate by 86%. This is concordant with previous reports that PHH3 increases mitotic counts by approximately 200%. 20, [27] [28] [29] [30] [31] In our study, PHH3 mitotic rates were more similar to H&E than MPM-2 mitotic rates. The clinical relevance of these increased mitotic counts reported using MPM-2 and PHH3 immunohistochemical stains is unknown, but AJCC 2009 mitotic rate cutoffs would not apply to the mitotic rate determined from immunostains, either with or without computer-assisted image analysis. Indeed, mitotic figures are identifiable even in nevi when immunohistochemical detection is used. 30 PHH3 staining was mostly restricted to cells in mitosis, although staining was seen in some cells in interphase (particularly melanophages). Macrophage staining has been described in studies of PHH3 in breast carcinoma and in melanocytic lesions. 16, 25 In anticipation of this confounding factor, we designed our study to use the red chromogen Fast Red, rather than diaminobenzidine, a common brown chromogen. As the Aperio software was optimized with diaminobenzidine as the default chromogen, this required replacement of default optical density values with those provided for Fast Red. Future studies might assess the utility of melanin bleaching methods combined with immunolabeling, but these techniques are time consuming and appear to have variable effects on antibody labeling. 32 Despite use of Fast Red as an alternative chromogen, some nonspecific background staining of melanin and debris persisted. This high background was more pronounced with MPM-2 but was also present in some PHH3-labeled sections. Ikenberg et al 33 recently reported improved PHH3 specificity by dual immunostaining with Melan-A/PHH-3 to avoid counting nonmelanocytic cells in mitosis. Dual immunostaining with a melanoma-specific antibody such as Melan-A could have improved the specificity of our results. However, the nuclear analysis algorithm (Aperio "Nuclear v9") used for the computer-assisted image analysis component of the study was not capable of detecting multiple chromogens.
Previously, Ladstein et al 29 reported no significant correlation between manual quantification of PHH3 staining and clinical outcome in melanoma. Our study differed in our use of the (Ser28) variant of the PHH3 antibody, whereas Ladstein and colleagues used the (Ser10) variant of PHH3. Published results with both variants (clones) appear similar, but no study has evaluated differences between the 2. Another difference was our evaluation of PHH3 on whole-slide images, in comparison with the tissue microarrays used by the previous study. 29 Although tissue microarrays permit evaluation of immunostaining on a large number of samples, it is impossible to definitively locate the mitotic hotspot. As mitotic activity may vary significantly throughout a tumor, it is also not possible to know whether the area of tumor selected for creation of the tissue microarray core reflects the area of maximum proliferative activity. A study of nevi by Glatz et al 30 found PHH3 staining in the upper half of the dermis to be 3 times that in the lower half of the dermis. It is reasonable that melanoma could show similar spatial heterogeneity in mitotic activity as well, complicating immunohistochemical studies of tissue microarrays. 13 As this manuscript was being prepared, Ladstein et al 34 reported in a follow-up study that PHH-3 correlated with better survival in nodular melanoma when studied on whole-tissue sections. Our use of computerassisted image analysis is a novel addition to these and other PHH-3 data.
The Aperio ScanScope digital image viewer used in this study was useful even without the companion image analysis software. In discussing mitotic rate, it is often overlooked that the precise measurement of an area equal to 1 mm 2 is as equally important as the precise detection of mitotic figures. Calculation of mitotic rate by conventional light microscopy requires that the area of each high-power field be calibrated for the individual microscope used. 6, 35 The Aperio digital image viewer enabled precise area measurements without microscope calibration and permitted precise measurements of irregularly shaped areas of interest that include the tumor and exclude noncontributory intervening stroma. The influence of tissue cellularity on mitotic rate calculation was also reduced, as selection of an area of "pure" tumor for mitotic rate calculation could be achieved on-screen with a selection tool more easily than with the rigid circular high-power field of a microscope. In tumors with moderate mitotic activity but low cellularity, this could mitigate the confounding effect of overall tumor cellularity. 11 Another consideration in use of the Aperio computerassisted image analysis software was the use of the nuclear analysis algorithm to detect immunolabeled mitotically active cells. As there is no nuclear envelope present during much of the M phase, staining is neither nuclear nor cytoplasmic. The nuclear algorithm software is designed to detect nuclei on the basis of features such as size, shape, border sharpness, and contour.
Our study is the second study of MPM-2 in melanoma, as the antibody was described in 1983. 36 MPM-2 appears more sensitive for detection of mitotic figures compared with both PHH3 and H&E, with a 159% increase in average manual mitotic count relative to H&E. The previous study of MPM-2 in melanoma reported a 48% increase in mitotic rate. 16 The high sensitivity and lower specificity of MPM-2 may be due to the fact that monoclonal antibodies against MPM-2 recognize >50 phosphoepitopes, including microtubule-associated proteins, components of the anaphase-promoting complex, phosphatases, and protein kinases including protein kinase CK2. 18 Unlike PHH3, MPM-2 did not correlate with outcomes in melanoma when used as a surrogate for traditional mitotic rate, regardless of the detection method.
Similar to previous studies, we find that mitosis detected by H&E significantly correlates with the likelihood of recurrence on multivariate analysis. 4, 5, [7] [8] [9] Mitotic rate by H&E may in fact carry more prognostic information than the presence or absence of ulceration, although the 2 are closely linked. 4, 7 Extracting the prognostic significance of mitotic rate may require a more complex approach than the current binary cutoff included in AJCC guidelines and will certainly require standardization. Although it seems that location of the "hotspot" was improved by immunostaining with either PHH3 or MPM-2, the prognostic value of mitotic rate is based on studies of H&E slide assessment. Whether the ease of locating the "hotspot" by immunohistochemistry has any significant relevance to prognosis in melanoma will require further study.
Challenges to standard reporting of mitotic rate include the time needed to accurately calculate field diameter, the time needed to locate the mitoses themselves, and interobserver variability. Our experience suggests that digital slide viewing software will facilitate faster and more accurate area calculation than microscopy alone. Neither of the antibodies in our study is sufficiently specific to merit routine clinical use. We do recommend that conventional mitotic rate based on H&E be included in diagnostic reports, as it continues to correlate strongly with clinical outcomes such as progression-free survival.
